Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.71 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279755 | 1.00 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL31108899 | 1.00 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL186368 | 1.00 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL185905 | 0.98 | CYP4F2 (0.68) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL186940 | 0.95 | CYP4F2 (0.65) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL25936769 | 0.95 | CYP4F2 (0.65) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL31108865 | 0.93 | CYP4F2 (0.63) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL187405 | 0.93 | CYP4F2 (0.63) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL3286744 | 0.93 | CYP4F2 (0.63) | CYP4F2CYP4A11HTTPKMTHRB | |
| SCHEMBL3278285 | 0.91 | CYP4F2 (0.60) | CYP4F2CYP4A11HTTPKMTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116924886-A | Synthesis method of 8-oxo-2,2,14,14-tetramethyl pentadecanedioic acid | 武汉武药科技有限公司 | 2023-10-24 | — | — | CN | claimed |
| WO-2023187833-A1 | A NOVEL SALT OF BEMPEDOIC ACID | ENALTEC LABS PRIVATE LIMITED (IN) | 2023-10-05 | — | — | WO | claimed |
| CN-114436837-A | Purification method of pipadiric acid intermediate | 甘李药业股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-20220081385-A1 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2022-03-17 | — | — | US | claimed |
| EP-3906231-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | Lupin Limited (IN) | 2021-11-10 | — | — | EP | claimed |
| CN-113227061-A | Novel salts and polymorphs of bipedac acid | 印度鲁宾有限公司 | 2021-08-06 | — | — | CN | claimed |
| WO-2020141419-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2020-07-09 | — | — | WO | claimed |
| EP-4695266-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024212248-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024213143-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| CN-114436821-B | Crystallization method of bevacizidine acid intermediate | 甘李药业股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-115504914-B | Preparation method of bevacizidine acid intermediate | 武汉武药科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-114436837-B | Purification method of bevacizidine acid intermediate | 甘李药业股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050043278-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | GLAS AMERICAS LLC | 2005-02-24 | — | — | US | disclosed |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HTT 1169/4885 |
| US-20220081385-A1 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | HADH, ALDH5A1, ACAD9 | CYP4F2 184/4885CYP4A11 197/4885HTT 1236/4885 |
| US-20050043278-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | CYP4F2 2115/4885CYP4A11 101/4885HTT 915/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HTT 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.